|
Name |
12beta-hydroxyverruculogen TR-2
|
Molecular Formula | C22H27N3O6 | |
IUPAC Name* |
(1S,2S,12S,15S)-1,2-dihydroxy-12-(2-hydroxy-2-methylpropyl)-7-methoxy-10,13,19-triazapentacyclo[11.7.0.03,11.04,9.015,19]icosa-3(11),4(9),5,7-tetraene-14,20-dione
|
|
SMILES |
CC(C)(C[C@H]1C2=C([C@@H]([C@]3(N1C(=O)[C@@H]4CCCN4C3=O)O)O)C5=C(N2)C=C(C=C5)OC)O
|
|
InChI |
InChI=1S/C22H27N3O6/c1-21(2,29)10-15-17-16(12-7-6-11(31-3)9-13(12)23-17)18(26)22(30)20(28)24-8-4-5-14(24)19(27)25(15)22/h6-7,9,14-15,18,23,26,29-30H,4-5,8,10H2,1-3H3/t14-,15-,18-,22-/m0/s1
|
|
InChIKey |
PIWNJAZCHHBADQ-FEHLYQECSA-N
|
|
Synonyms |
CHEMBL2229115; 12beta-hydroxyverruculogen TR-2
|
|
CAS | NA | |
PubChem CID | 76318715 | |
ChEMBL ID | CHEMBL2229115 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 429.5 | ALogp: | -0.3 |
HBD: | 4 | HBA: | 6 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 126.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 31 | QED Weighted: | 0.584 |
Caco-2 Permeability: | -5.237 | MDCK Permeability: | 0.00000764 |
Pgp-inhibitor: | 0.031 | Pgp-substrate: | 0.495 |
Human Intestinal Absorption (HIA): | 0.039 | 20% Bioavailability (F20%): | 0.016 |
30% Bioavailability (F30%): | 0.174 |
Blood-Brain-Barrier Penetration (BBB): | 0.236 | Plasma Protein Binding (PPB): | 47.83% |
Volume Distribution (VD): | 1.053 | Fu: | 44.33% |
CYP1A2-inhibitor: | 0.014 | CYP1A2-substrate: | 0.105 |
CYP2C19-inhibitor: | 0.12 | CYP2C19-substrate: | 0.795 |
CYP2C9-inhibitor: | 0.276 | CYP2C9-substrate: | 0.755 |
CYP2D6-inhibitor: | 0.004 | CYP2D6-substrate: | 0.167 |
CYP3A4-inhibitor: | 0.186 | CYP3A4-substrate: | 0.929 |
Clearance (CL): | 7.145 | Half-life (T1/2): | 0.592 |
hERG Blockers: | 0.007 | Human Hepatotoxicity (H-HT): | 0.653 |
Drug-inuced Liver Injury (DILI): | 0.982 | AMES Toxicity: | 0.007 |
Rat Oral Acute Toxicity: | 0.195 | Maximum Recommended Daily Dose: | 0.969 |
Skin Sensitization: | 0.11 | Carcinogencity: | 0.046 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.007 |
Respiratory Toxicity: | 0.884 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002846 | 0.840 | D06YFA | 0.283 | ||||
ENC001958 | 0.732 | D02IQY | 0.275 | ||||
ENC003264 | 0.732 | D01TSI | 0.261 | ||||
ENC003265 | 0.613 | D0J4JM | 0.259 | ||||
ENC002064 | 0.552 | D0V3ZA | 0.253 | ||||
ENC000837 | 0.534 | D09NNH | 0.253 | ||||
ENC002698 | 0.523 | D0SP3D | 0.253 | ||||
ENC002260 | 0.496 | D0G8NJ | 0.250 | ||||
ENC005479 | 0.491 | D06HBQ | 0.245 | ||||
ENC001060 | 0.491 | D04UTT | 0.244 |